Patents by Inventor Burt Adelman

Burt Adelman has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220291232
    Abstract: Methods and assays for determining the activation level of the plasma kallikrein (pKal) system and the uses thereof for assessing the activity of pKal modulators on the pKal system.
    Type: Application
    Filed: December 20, 2021
    Publication date: September 15, 2022
    Applicant: Takeda Pharmaceutical Company Limited
    Inventors: Daniel J. Sexton, Ryan Faucette, Jon A. Kenniston, Gregory P. Conley, Andrew Nixon, Christopher TenHoor, Burt Adelman
  • Patent number: 11390687
    Abstract: Described herein are bispecific antibodies that bind to plasma kallikrein (pKal) and Factor XII and methods of producing and using such bi-specific antibodies for treating diseases or disorders associated with the contact system, e.g., hereditary angioedema or thrombosis.
    Type: Grant
    Filed: December 31, 2015
    Date of Patent: July 19, 2022
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Stephen R. Comeau, Andrew Nixon, Niksa Kastrapeli, Jon A. Kenniston, Gregory P. Conley, Shauna Mason, Allison P. Lindberg, Kristopher Kopacz, Burt Adelman
  • Patent number: 11372002
    Abstract: Methods and assays for determining the activation level of the plasma kallikrein (pKal) system and the uses thereof for assessing the activity of pKal modulators on the pKal system.
    Type: Grant
    Filed: October 17, 2014
    Date of Patent: June 28, 2022
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Daniel J. Sexton, Ryan Faucette, Jon A. Kenniston, Gregory P. Conley, Andrew Nixon, Christopher TenHoor, Burt Adelman
  • Publication number: 20220170936
    Abstract: The present disclosure provides methods of evaluating a subject, e.g., a subject at risk for or suffering from a pKal-mediated or bradykinin-mediated disorder, based on values (e.g., percentages) of intact and/or cleaved kininogen in a sample of the subject. Provided methods permit analysis of patients with plasma kallikrein-mediated angioedema (KMA), or other diseases mediated by pKal useful in the evaluation and treatment. Such methods can involve the use of a detection agent that preferentially binds cleaved kininogen or intact kininogen.
    Type: Application
    Filed: October 1, 2021
    Publication date: June 2, 2022
    Applicant: Takeda Pharmaceutical Company Limited
    Inventors: Daniel J. Sexton, Ryan Faucette, Jon A. Kenniston, Gregory P. Conley, Andrew Nixon, Christopher TenHoor, Burt Adelman, Yung Chyung
  • Publication number: 20220169749
    Abstract: Provided herein are plasma kallikrein antibodies binding to active plasma kallikrein and methods of using such antibodies in preventing hereditary angioedema attack or reducing the rate of hereditary angioedema attack.
    Type: Application
    Filed: October 13, 2021
    Publication date: June 2, 2022
    Applicant: Takeda Pharmaceutical Company Limited
    Inventors: Yung Chyung, Burt Adelman, Daniel J. Sexton
  • Patent number: 11286307
    Abstract: Provided herein are plasma kallikrein antibodies binding to active plasma kallikrein and methods of using such antibodies in treating and preventing hereditary angioedema attack, such method may involve a first treatment period and optionally, a second treatment period. Also provided are methods of using such antibodies in treating hereditary angioedema involving a single dose of the antibody to a subject who has undergone a prior HAE treatment, followed by multiple doses of the same antibody if the subject experiences an HAE attack after the single dose.
    Type: Grant
    Filed: December 9, 2016
    Date of Patent: March 29, 2022
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Burt Adelman, Yung Chyung, Jennifer Schranz
  • Patent number: 11156612
    Abstract: The present disclosure provides methods of evaluating a subject, e.g., a subject at risk for or suffering from a pKal-mediated or bradykinin-mediated disorder, based on values (e.g., percentages) of intact and/or cleaved kininogen in a sample of the subject. Provided methods permit analysis of patients with plasma kallikrein-mediated angioedema (KMA), or other diseases mediated by pKal useful in the evaluation and treatment. Such methods can involve the use of a detection agent that preferentially binds cleaved kininogen or intact kininogen.
    Type: Grant
    Filed: January 17, 2014
    Date of Patent: October 26, 2021
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Daniel J. Sexton, Ryan Faucette, Jon A. Kenniston, Gregory P. Conley, Andrew Nixon, Christopher TenHoor, Burt Adelman, Yung Chyung
  • Patent number: 11084884
    Abstract: Provided herein are plasma kallikrein binding proteins such as antibodies binding to active plasma kallikrein and methods of using such proteins in treating hereditary angioedema.
    Type: Grant
    Filed: January 21, 2015
    Date of Patent: August 10, 2021
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Daniel J. Sexton, Burt Adelman, Yung Chyung, Christopher TenHoor, Jon A. Kenniston, Ryan Faucette, Ryan Iarrobino, Joseph Biedenkapp
  • Publication number: 20210230299
    Abstract: Disclosed herein are anti-Factor XIIa antibodies and methods of using such for treating diseases associated with Factor XII, including diseases associated with contact system activation, plasma prekallikrein signaling (e.g., hereditary angioedema), and ocular diseases.
    Type: Application
    Filed: December 29, 2020
    Publication date: July 29, 2021
    Applicant: Dyax Corp.
    Inventors: Shauna Mason, Jon A. Kenniston, Andrew Nixon, Daniel J. Sexton, Stephen R. Comeau, Burt Adelman
  • Publication number: 20210087293
    Abstract: Provided herein are plasma kallikrein binding proteins such as antibodies binding to active plasma kallikrein and methods of using such proteins in treating hereditary angioedema.
    Type: Application
    Filed: September 2, 2020
    Publication date: March 25, 2021
    Applicant: Dyax Corp.
    Inventors: Daniel J. Sexton, Burt Adelman, Yung Chyung, Christopher TenHoor, Jon A. Kenniston, Ryan Faucette, Ryan Iarrobino, Joseph Biedenkapp
  • Patent number: 10913802
    Abstract: Disclosed herein are anti-Factor XIIa antibodies and methods of using such for treating diseases associated with Factor XII, including diseases associated with contact system activation, plasma prekallikrein signaling (e.g., hereditary angioedema), and ocular diseases.
    Type: Grant
    Filed: July 21, 2016
    Date of Patent: February 9, 2021
    Assignee: Dyax Corp.
    Inventors: Shauna Mason, Jon A. Kenniston, Andrew Nixon, Daniel J. Sexton, Stephen R. Comeau, Burt Adelman
  • Publication number: 20200371120
    Abstract: Methods, kits and compositions for diagnosing and treating autoimmue diseases such as rheumatiodi arthritis, Crohn's disease, and ulcerative colitis.
    Type: Application
    Filed: April 15, 2020
    Publication date: November 26, 2020
    Applicant: Dyax Corp.
    Inventors: Daniel J. Sexton, Burt Adelman, Andrew Nixon
  • Patent number: 10648990
    Abstract: Methods, kits and compositions for diagnosing and treating autoimmue diseases such as rheumatiodi arthritis, Crohn's disease, and ulcerative colitis.
    Type: Grant
    Filed: September 14, 2018
    Date of Patent: May 12, 2020
    Assignee: Dyax Corp.
    Inventors: Daniel J. Sexton, Burt Adelman, Andrew Nixon
  • Publication number: 20190120862
    Abstract: Methods, kits and compositions for diagnosing and treating autoimmue diseases such as rheumatiodi arthritis, Crohn's disease, and ulcerative colitis.
    Type: Application
    Filed: September 14, 2018
    Publication date: April 25, 2019
    Applicant: Dyax Corp.
    Inventors: Daniel J. Sexton, Burt Adelman, Andrew Nixon
  • Publication number: 20190002584
    Abstract: Disclosed herein are anti-Factor Xlla antibodies and methods of using such for treating diseases associated with Factor XII, including diseases associated with contact system activation, plasma prekallikrein signaling (e.g., hereditary angioedema), and ocular diseases.
    Type: Application
    Filed: July 21, 2016
    Publication date: January 3, 2019
    Applicant: Dyax Corp.
    Inventors: Shauna Mason, Jon A. Kenniston, Andrew Nixon, Daniel J. Sexton, Stephen R. Comeau, Burt Adelman
  • Publication number: 20180362664
    Abstract: Provided herein are plasma kallikrein antibodies binding to active plasma kallikrein and methods of using such antibodies in treating and preventing hereditary angioedema attack, such method may involve a first treatment period and optionally, a second treatment period. Also provided are methods of using such antibodies in treating hereditary angioedema involving a single dose of the antibody to a subject who has undergone a prior HAE treatment, followed by multiple doses of the same antibody if the subject experiences an HAE attack after the single dose.
    Type: Application
    Filed: December 9, 2016
    Publication date: December 20, 2018
    Applicant: Dyax Corp.
    Inventors: Burt Adelman, Yung Chyung, Jennifer Schranz
  • Publication number: 20180298110
    Abstract: Provided herein are plasma kallikrein antibodies binding to active plasma kallikrein and methods of using such antibodies in preventing hereditary angioedema attack or reducing the rate of hereditary angioedema attack.
    Type: Application
    Filed: March 30, 2016
    Publication date: October 18, 2018
    Applicant: Dyax Corp.
    Inventors: Yung Chyung, Burt Adelman, Daniel J. Sexton
  • Patent number: 10101344
    Abstract: Methods, kits and compositions for diagnosing and treating autoimmune diseases such as rheumatiodi arthritis, Crohn's disease, and ulcerative colitis.
    Type: Grant
    Filed: October 17, 2014
    Date of Patent: October 16, 2018
    Assignee: Dyax Corp.
    Inventors: Daniel J. Sexton, Burt Adelman, Andrew Nixon
  • Publication number: 20180118851
    Abstract: Described herein are bispecific antibodies that bind to plasma kallikrein (pKal) and Factor XII and methods of producing and using such bi-specific antibodies for treating diseases or disorders associated with the contact system, e.g., hereditary angioedema or thrombosis. One aspect of the present disclosure is a bispecific antibody, comprising: a first polypeptide that comprises a light chain of a first antibody, the light chain comprising a light chain variable region (VL) and a light chain constant region (CL) (e.g., a kappa light chain or a lambda light chain); and a second polypeptide that comprises a heavy chain of the first antibody, the heavy chain comprising a heavy chain variable region (VH) and a heavy chain constant region (CH).
    Type: Application
    Filed: December 31, 2015
    Publication date: May 3, 2018
    Applicant: Dyax Corp.
    Inventors: Stephen R. Comeau, Andrew Nixon, Niksa Kastrapeli, Jon A. Kenniston, Gregory P. Conley, Shauna Mason, Allison P. Lindberg, Kristopher Kopacz, Burt Adelman
  • Publication number: 20170002094
    Abstract: Provided herein are plasma kallikrein binding proteins such as antibodies binding to active plasma kallikrein and methods of using such proteins in treating hereditary angioedema.
    Type: Application
    Filed: January 21, 2015
    Publication date: January 5, 2017
    Applicant: Dyax Corp.
    Inventors: Daniel J. Sexton, Burt Adelman, Yung Chyung, Christopher TenHoor, Jon A. Kenniston, Ryan Faucette, Rayan larrobino, Joe Biedenkapp